Integris Health Secures Capital Investment
Integris Health, a prominent medical devices company, has successfully raised primary capital from a diverse consortium of notable investors, such as Mukul Agarwal and the India SME Fund. The firm is also supported by Everstone Capital.
These funds will facilitate the company’s expansion into various therapeutic fields, including:
- In-vitro diagnostics
- Laboratory solutions
Integris Health plans to achieve this through both strategic acquisitions and internal product development initiatives, as detailed in a recent press release.
Leadership and Future Plans
In 2024, Probir Das was appointed as CEO to spearhead the company’s growth strategy. Integris Health aims to go public by the end of 2025 and has already begun preparations for its initial public offering (IPO).
About Integris Health
Established in 2008 by Gurmit Singh Chugh, Integris Health is a medical devices firm focusing on:
- Interventional cardiology
- Cardiovascular therapy
- Vascular surgery
The company operates as a fully integrated entity, managing the entire process from product development and manufacturing to sales and distribution. Its manufacturing facilities are located in Germany, the Netherlands, and India, while it boasts a sales presence in over 50 markets.
Strategic Partnerships and Innovation
Over the years, Integris Health has forged strategic partnerships with:
- Leading hospitals
- Engineering institutes
- Global med-tech device companies
- Interventional cardiologists
The company combines exceptional German engineering and high-quality standards with India’s entrepreneurial spirit, aiming to manufacture innovative products at competitive prices.
Integris Health is dedicated to empowering the Indian med-tech device industry by harnessing its advanced research and development (R&D), strategic alliances, strong distribution network, and the cost effectiveness of Indian manufacturing.